Monte Rosa Therapeutics (GLUE) Other financing activities (2020 - 2024)

Monte Rosa Therapeutics' Other financing activities history runs 5 years deep, the most recent figure standing at $229000.0 for Q4 2024.

• In Q4 2024, Other financing activities fell 16.73% year-over-year to $229000.0; the TTM figure through Dec 2024 stood at $504000.0 (down 61.96% YoY), while the FY2024 annual figure was $527000.0, down 8.82% from the prior year.
• Other financing activities was $229000.0 for Q4 2024 at Monte Rosa Therapeutics, down from $275000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $18.5 million in Q2 2021 to a low of -$231000.0 in Q4 2021.
• Historically, Other financing activities has averaged $2.3 million across 5 years, with a median of $263500.0 in 2020.
• Biggest YoY gain for Other financing activities was 812.7% in 2021; the steepest drop was 2410.0% in 2021.
• A 5-year view of Other financing activities shows it stood at $10000.0 in 2020, then tumbled by 2410.0% to -$231000.0 in 2021, then surged by 245.45% to $336000.0 in 2022, then dropped by 18.15% to $275000.0 in 2023, then decreased by 16.73% to $229000.0 in 2024.
• The last three Other financing activities figures came in at $229000.0 (Q4 2024), $275000.0 (Q4 2023), and $336000.0 (Q4 2022), per Business Quant data.